deltatrials
Recruiting PHASE1 INTERVENTIONAL 8-arm NCT06771219

SLV-154 Treatment of Metastatic Solid Tumors

A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors

Sponsor: Solve Therapeutics

Conditions Breast Cancer Metastatic Cervical Cancer Metastatic Endometrial Cancer NSCLC Ovarian Cancer SCLC Sarcoma Squamous Cell Cancer of Head and Neck (SCCHN) Thyroid Cancer Urothelial Cancer
Interventions SLV-154
Updated 7 times since 2025 Last updated: Jan 22, 2026 Started: May 14, 2025 Primary completion: Jan 31, 2027 Completion: Apr 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Cancer Metastatic and Cervical Cancer Metastatic and is currently actively recruiting participants. Solve Therapeutics leads this study, which shows 7 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshotNot Yet Recruiting~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshotRecruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

7 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1

  2. Oct 2025 — Feb 2026 [monthly]

    Recruiting PHASE1

  3. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

  4. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  5. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE1

▶ Show 2 earlier versions

  1. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Feb 2025 — Jun 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Solve Therapeutics
Data source: Solve Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations